Skip to main content

Table 6 Correlation analysis of YAP1 promoter methylation with the clinical parameters in Indian breast cancer patients

From: Aberrant Promoter Methylation of YAP Gene and its Subsequent Downregulation in Indian Breast Cancer Patients

Characteristics Cases (%) Unmethylated (%) Methylated (%) p value
Age (years)
≤50 78 (56.93) 21 (26.92) 57 (73.08) 0.571
>50 59 (43.07) 19 (32.20) 40 (67.80)  
Age at menarche
≤12 26 (18.98) 8 (30.77) 18 (69.23) 0.815
>12 111 (81.02) 32 (28.83) 79 (71.17)  
Menopausal status
Premenopausal 40 (29.20) 12 (30) 28 (70) 1
Postmenopausal 97 (70.80) 28 (28.87) 69 (71.13)  
Age at menopause
≤45 33 (34.02) 12 (36.36) 21 (63.64) 0.249
>45 64 (65.98) 16 (25) 48 (75)  
ER status
Positive 81 (59.12) 27 (33.33) 54 (66.67) 0.252
Negative 56 (40.88) 13 (23.21) 43 (76.79)  
PR status
Positive 47 (34.31) 12 (25.53) 35 (74.47) 0.556
Negative 90 (65.69) 28 (31.11) 62 (68.89)  
Her2 status
Positive 66 (48.18) 18 (27.27) 48 (72.73) 0.708
Negative 71 (51.82) 22 (30.99) 49 (69.01)  
Molecular subtypes of breast cancer
Luminal A 46 (33.58) 16 (34.78) 30 (65.22) 0.584
Luminal B 38 (27.74) 12 (31.58) 26 (68.42)  
Her2-enriched 28 (20.44) 6 (21.43) 22 (78.57)  
TNBC 25 (18.25) 6 (24) 19 (76)  
Tumor size
≤5 55 (40.15) 15 (27.27) 40 (72.73) 0.707
>5 82 (59.85) 25 (30.49) 57 (69.51)  
Lymph node status
Positive 99 (72.26) 29 (29.29) 70 (70.71) 1
Negative 38 (27.74) 11 (28.95) 27 (71.05)  
Clinical stage
I+II 45(32.85) 11 (24.44) 34 (75.56) 0.43
III+IV 92(67.15) 29 (31.52) 63 (68.48)  
Histological grade
I+II 95 (69.34) 27 (28.42) 68 (71.58) 0.839
III 42 (30.66) 13 (30.95) 29 (69.05)  
  1. p value (Fisher’s Exact Test), Bonferroni significance level ≤ 0.005